International Stem Cell (ISCO) EBT Margin (2010 - 2026)
International Stem Cell (ISCO) posted quarterly EBT Margin of 9.42% for Q4 2025, down 991.0% year-over-year from 1.06% in Q4 2024, and up 46.99% quarter-over-quarter from 17.77% in Q3 2025.
International Stem Cell (ISCO) EBT Margin (2010 - 2026) Analysis & Trends
International Stem Cell (ISCO) has reported EBT Margin for 16 consecutive years, with 9.42% the latest figure, recorded in Q4 2025.
- In Q4 2025, EBT Margin fell 991.0% year-over-year to 9.42%; the TTM figure through Dec 2025 stood at 22.08% (down 1237.0% YoY), while the FY2025 annual figure was 86.95%, down 302.0% from the prior year.
- EBT Margin rose to 9.42% in Q4 2025 per ISCO's latest filing, from 17.77% in the prior quarter.
- Across five years, EBT Margin topped out at 6.58% in Q4 2022 and bottomed at 50.87% in Q3 2021.
- Historically, EBT Margin has averaged 17.26% across 5 years, with a median of 14.8% in 2023.
- Annual changes were most pronounced in 2022 — EBT Margin jumped 4906 bps — and 2025, when it plunged 3152 bps.
- International Stem Cell's EBT Margin stood at 19.21% in 2021, then jumped by 134 bps to 6.58% in 2022, then plunged by 361 bps to 17.2% in 2023, then soared by 103 bps to 0.49% in 2024, then plunged by 2020 bps to 9.42% in 2025.
- Business Quant data shows ISCO's EBT Margin at 9.42% in Q4 2025, 17.77% in Q3 2025, and 18.39% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 13.77% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -2.67% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -25.06% |
| 10 | International Stem Cell | 4.32 Mn | 3.23 Mn | 1.46 Mn | -2.58% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.85% |
| Dec 31, 2025 | -9.42% |
| Sep 30, 2025 | -17.77% |
| Jun 30, 2025 | -18.39% |
| Mar 31, 2025 | -43.92% |
| Dec 31, 2024 | 0.49% |
| Sep 30, 2024 | -5.74% |
| Jun 30, 2024 | -21.66% |
| Mar 31, 2024 | -12.40% |
| Dec 31, 2023 | -17.20% |
| Sep 30, 2023 | -6.64% |
| Jun 30, 2023 | -9.72% |
| Mar 31, 2023 | -1.63% |
| Dec 31, 2022 | 6.58% |
| Sep 30, 2022 | -19.67% |
| Jun 30, 2022 | -0.10% |
| Mar 31, 2022 | -0.45% |
| Dec 31, 2021 | -19.21% |
| Sep 30, 2021 | -50.87% |
| Jun 30, 2021 | -49.15% |